New hope for advanced breast cancer: experimental drug enters human trials
NCT ID NCT03616587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called AZD9833, alone or with other medicines, in women with a specific type of advanced breast cancer (ER-positive, HER2-negative). The main goals are to check safety and find the right dose. About 396 women will take part. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER+ / HER2- ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Sarasota, Florida, 34232, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Salt Lake City, Utah, 84112, United States
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 8036, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Madrid, 28050, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
Valencia, 46010, Spain
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
London, SW2 6JJ, United Kingdom
-
Research Site
Manchester, M20 4GJ, United Kingdom
-
Research Site
Sutton, SM1 2DL, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.